NCT00287261View on ClinicalTrials.gov

A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
MyelofibrosisMyeloid Metaplasia
Interventions
DRUG

zoledronic acid

4 mg IV every 3 weeks for 36 weeks

Trial Locations (6)

3000

University Hospital Leuven, Leuven

4029

Cancer Care Services, Brisbane

24105

Medizinische Klinik Kiel, Kiel

30800

Hospital Rafael éndez, Murcia

31096

RAMBAM Medical Center and Technion, Haifa

93000

Hopital Avicenne and Paris 13 University, Bobigny

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT00287261 - A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) | Biotech Hunter | Biotech Hunter